id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5625-0012,FDA,FDA-2017-D-5625,Draft Guidance for Industry and FDA_name_Recommendations for Dual 510(k) and CLIA Wavier by Application Studies_11-29-2018,Other,Guidance,2018-11-29T05:00:00Z,2018,11,2018-11-29T05:00:00Z,2019-02-28T04:59:59Z,2024-11-12T22:50:42Z,,1,0,090000648390cf30
FDA-2017-D-5625-0011,FDA,FDA-2017-D-5625,"Recommendations for Dual 510(k) and Clinical Laboratory Improvement
Amendments Waiver by Application Studies; Draft Guidance for Industry
and Food and Drug Administration Staff; Availability",Notice,Notice of Availability,2018-11-29T05:00:00Z,2018,11,2018-11-29T05:00:00Z,2019-02-28T04:59:59Z,2024-11-12T22:50:46Z,2018-25960,1,0,090000648390c0b9
FDA-2017-D-5625-0005,FDA,FDA-2017-D-5625,"Recommendations for Dual 510(k) and Clinical Laboratory Improvement
Amendments Waiver by Application Studies; Draft Guidance for Industry
and Food and Drug Administration Staff; Availability; Extension of  Comment Period",Notice,Notice of Availability,2018-01-26T05:00:00Z,2018,1,2018-01-26T05:00:00Z,2018-03-31T03:59:59Z,2018-03-31T01:00:39Z,2018-01350,0,0,0900006482e6c0cd
FDA-2017-D-5625-0004,FDA,FDA-2017-D-5625,"Request for Extension from Coalition for CLIA Waiver Reform (Epstein Becker & Green, P.C.)",Other,Electronic Regulation from Form,2018-01-08T05:00:00Z,2018,1,2018-01-08T05:00:00Z,,2018-01-08T16:23:20Z,,0,0,0900006482d9db46